CAP Publishes Guideline for PD-L1 Testing of Patients with Lung Cancer...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: April 29, 2024

Union Pacific Highlights Commitment to Safety, Community and Sustainability in 2023 Building America Report • CHOP Study Finds Healthcare Providers Play Crucial Role in Guiding Autistic Adolescents and Their Families into Adulthood • Plant Vogtle Unit 4 Achieves Commercial Operations • Ten Pennsylvania Communities Selected to Participate in Community Revitalization Initiative • InventHelp Inventor Develops New Religious-Themed Game (BRK-4269) • Atavus Football Announces Strategic Partnership with Hudl, Becoming an Official Preferred Partner • Enter to Win Florida Realtors® ENVY Award • New Perspective closes on more than $200 Million in capital and establishes a programmatic relationship for growth • USPAACC Announces CelebrASIAN 2024 Procurement + Business Conference, May 29-31, The Hotel at Avalon, Autograph Collection, Alph • Yamaha Publicly Demonstrates Yamaha Hydrogen-Powered Golf Car for First Time • Natron Energy Achieves First-Ever Commercial-Scale Production of Sodium-Ion Batteries in the U.S. • Designer Secret Revealed: aerMist Misters Enhance Outdoor Living Spaces • Struck by Lightning: How Businesses Can Become More Resilient – Triple-I and LPI • 20/20 Onsite Launches ‘Vision for Southbridge’ Program to Provide Eye Care to All Southbridge, MA Public Schools • SHATTERPROOF AND ANTHEM BLUE CROSS AND BLUE SHIELD FOUNDATION PARTNER TO REDUCE HEALTHCARE STIGMA AROUND SUBSTANCE USE DISORDER • Cooler Master Unveils New CALIBER X2C and R3C Gaming Chairs for the Ultimate Cool Comfort • Disney Celebrates World Wish Day ® by Granting Over One Hundred Wishes Around the World • Health-E Commerce® shares 5 ways to use FSA or HSA funds to support women's health • MoPOP Announces Revamped Volunteer Program With Exclusive Benefits • Soleo Health Unveils Pharmacy in Jackson, MS; Marks Pharmacy Entry Into State

CAP Publishes Guideline for PD-L1 Testing of Patients with Lung Cancer

NORTHFIELD, Ill. , April 16 /Businesswire/ - The College of American Pathologists (CAP) in collaboration with the International Association for the Study of Lung Cancer (IASLC), Pulmonary Pathology Society (PPS), Association for Molecular Pathology (AMP) and the LUNGevity Foundation have developed evidence-based recommendations for the testing of immunotherapy biomarkers, including Programmed Cell Death Ligand-1 (PD-L1) and tumor mutation burden (TMB) in patients with non-small cell lung carcinoma (NSCLC).

“Many lung cancer patients may benefit from therapies that can harness the immune system, including anti-PD-1 or PD-L1 therapies. However, the benefit of these therapies is not universal, and clinically validated biomarkers that can help predict response include PD-L1 expression and proposed tumor mutational burden (TMB),” explains Larissa Furtado, MD, FCAP. “This guideline is intended to provide an overview of the clinical rationale for the use of PD-L1 and tumor mutational burden (TMB) testing for patients with non-small lung cancer. It highlights the technical challenges of PD-L1 testing and interpretation, including some of the complexities introduced by the development of divergent companion diagnostic PD-L1 tests for different immune checkpoint blockade therapies. It outlines the rationale for use of TMB and the current limitations of this test for lung cancer patients.”

This guideline, now available in an early online release in the Archives of Pathology & Laboratory Medicine, was driven by production of PD-L1 assays and scoring criteria that have evolved with individual therapies. At the same time, for reasons of cost and access, PD-L1 IHC antibodies and assays developed outside of the scope of randomized controlled trials have garnered widespread use.

“Clinical trials have demonstrated that drugs that block Programmed Cell Death 1 (PD-1), and PD-L1 lead to significant improvements in both response and survival relative to conventional cytotoxic chemotherapy for patients with advanced stage NSCLC,” explained guideline update co-chair Lynette Sholl, MD, FCAP.

The expert panel recognized that the regulatory-approved diagnostics are clinically validated, and as such their use is recommended. However, most laboratories may be relying on laboratory developed tests (LDTs) because of limited access to a full suite of approved clones and platforms, as well as the increased cost of running companion diagnostic-labeled assays. “To ensure patient access to PD-L1 testing, particularly at the local level, we endorse the use of LDTs and validated PD-L1 IHC (LDTs) following technical validation against one or more of the approved companion diagnostic PD-L1 assays,” said Dr. Furtado.

With six recommendations, the guideline provides data and details regarding the efficacy and utility of PD-L1 testing of patients with lung cancer. This new guideline was developed by IASLC, PPS, the LUNGevity Foundation and the CAP Center, which develops evidence-based guidelines and consensus statements related to the practice of pathology and laboratory medicine. Through this work, the CAP and its members continually improve the quality of diagnostic medicine and patient outcomes. Current tools, resources, and information for the PD-L1 Testing of Patients with Lung Cancer Guideline can be found on the guideline webpage on cap.org.

About the College of American Pathologists

As the world’s largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, visit the CAP Newsroom, CAP.org and yourpathologist.org to watch pathologists at work and see the stories of the patients who trust them with their care.